Association Between PAI-1 Activity Levels and t-PA Antigen with Glycemic Status in Prediabetic Population by Benyamin, Andi Fachruddin et al.
200 
ORIGINAL ARTICLE
Acta Medica Indonesiana - The Indonesian Journal of Internal Medicine
Association Between PAI-1 Activity Levels and t-PA Antigen 
with Glycemic Status in Prediabetic Population
Andi F. Benyamin, Rahmawati Minhajat, Dimas Bayu, Sahyuddin Saleh, 
Tutik Harjianti
Department of Internal Medicine, Faculty of Medicine, University of Hasanuddin, Makassar, Indonesia.
Corresponding Author:
Andi Fachruddin Benyamin. MD., PhD. Division of Hematology and Medical Oncology, Department of Internal 
Medicine, Faculty of Medicine, University of Hasanuddin. University of Hasanuddin Hospital, A building, 5th floor. 
Jl. Tamalanrea Km.11, Makassar-90245, Indonesia. email: andifach@yahoo.co.id, rahmawati.minhajat@gmail.
com, dimasbayu_md@live.com.
ABSTRAK
Tujuan: mengevaluasi hubungan antara defek fibrinolisis dengan status glikemik pada populasi prediabetik 
dengan menilai kadar antigen t-PA dan aktivitas PAI-1. Metode: penelitian ini merupakan penelitian observasional 
dengan pendekatan potong lintang. Sebanyak 72 orang, usia 30-50 tahun yang memenuhi kriteria inklusi, dimana 
diagnosis diabetes mellitus (DM) dan status glikemik ditegakkan berdasarkan kriteria American Diabetes 
Association (ADA). Kadar PAI-1 dan kadar antigen t-PA diukur secara kuantitatif dengan metode enzyme-linked 
immunosorbent assay (ELISA). Analisis antara kadar antigen t-PA dan aktivitas PAI-1 menggunakan uji ANOVA. 
Hasil: kadar antigen t-PA secara bermakna lebih tinggi pada subyek toleransi gula terganggu (TGT), subyek 
glukosa darah puasa terganggu (GDPT) dan glukosa darah puasa terganggu (GDPT) dibanding toleransi glukosa 
normal (TGN) (p=0.047). Aktivitas PAI-1 secara bermakna lebih tinggi pada subyek TGT, GDPT dan subyek 
GDPT dibanding TGN (p=0.024). Ada hubungan bermakna antara status glikemik pada subyek prediabetik dengan 
aktivitas PAI-1 (p=0.04). Kesimpulan: kadar antigen t-PA dan aktivitas PAI-1 secara bermakna lebih tinggi pada 
subyek prediabetik dibanding TGN, dan didapatkan hubungan bermakna antara status glikemik subyek prediabetik 
dengan aktivitas PAI-1.
Kata kunci: prediabetik, efek fibrinolisis, plasminogen activator inhibitor-1 (PAI-1), antigen tissue-type 
plasminogen activator (t-PA).
ABSTRACT
Aim: to evaluate an association between fibrinolysis defect and glycemic status in prediabetic population by 
assessing the levels of t-PA antigen and PAI-1 activity. Methods: it was an observational study with cross-sectional 
approach. There were 72 subjects aged 30-50 years who had met the inclusion criteria. The diagnosis of diabetes 
mellitus (DM) and glycemic index were determined based on the American Diabetes Association (ADA) criteria. 
The PAI-1 and t-PA antigen levels were measured quantitatively using enzyme-linked immunosorbent assay (ELISA). 
Analysis between the levels of t-PA antigen and PAI-1 activity was performed using ANOVA. Results: the t-PA 
antigen level was significantly higher in subjects with impaired glucose tolerance (IGT) and impaired fasting blood 
glucose (IFBG) as well as subject with impaired fasting blood glucose (IFBG) than those with normal glucose 
tolerance (NGT) (p=0.047). The PAI-1 activity was significantly higher in subjects with IGT, IFBG and subjects 
with IFBG than NGT (p=0.024). There was a significant association between glycemic status in prediabetic subjects 
and PAI-1 activity (p=0.04). Conclusion: the level of t-PA antigen and PAI-1 activity were significantly higher 
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INTRODUCTION
The mechanism of the atherothrombosis 
development in prediabetic population has not 
been fully understood. It is assumed that it occurs 
due to insulin resistance in addition to hemostatic 
disorders, which involve hypercoagulability 
and fibrinolysis defect.1,2 The effectiveness of 
fibrinolysis mainly depends on the activity of 
tissue-type plasminogen activator (t-PA), which 
is released by damaged vascular wall in order 
to alter plasminogen into active plasmin on 
thrombus surface that leads to the development 
of thrombolysis. Afterwards, it will be rapidly 
inhibited by Plasminogen Activator Inhibitor-1 
(PAI-1) activity in circulation.1 Numerous 
prospective studies have demonstrated that 
fibrinolysis defect also has contribution in the 
development of vascular event, particularly 
atherothrombosis in various populations 
including patients with diabetes mellitus (DM).2-5
It has been proven that DM patients have 
higher risk for developing cardiovascular 
disease, peripheral arterial disease and stroke 
than non-diabetic population.6 The morbidity 
and mortality rate due to cardiovascular events 
in general population has been decreased in the 
last few years. However, the phenomenon has 
not been demonstrated in diabetic population.7 
The high prevalence of DM will have various 
impacts on morbidity and mortality due to 
its potential complications that eventually 
will cause increased health care cost.8 The 
severity of hyperglycemia and the duration of 
suffering DM type 2 have been consistently 
demonstrated to bring some effects on the 
development of microvascular complications. 
However, similar issue has not been found 
for macrovascular complications.9,10 It is 
assumed that the differences may occur due to 
a metabolic disorder in prediabetic phase and 
in turn, it is believed that the differences will 
play a role in the development of macrovascular 
complications.9 Prediabetic population consists 
of subjects with impaired glucose tolerance 
(IGT) and subjects with impaired fasting blood 
glucose (IFBG). Both groups are considered as 
those who are in intermediate metabolic state, 
which is between the phase of normal glucose 
tolerance and DM.11
A study conducted by Rewers et al12 in a 
population in Colorado, United States found that 
the prevalence of CHD in subjects with IGT has 
reached 1.5-2.6 folds compared to subjects with 
normal glucose tolerance (NGT). Results from 
Framingham Offspring Study (FOS) showed 
that there is a significant association between 
the levels of fasting insulin and the levels of 
PAI-1, t-PA antigens, factor VII, factor vWF and 
fibrinogen in a population with normal glucose 
levels; while in prediabetic population, only the 
marker of fibrinolysis defect (PAI-1 levels and 
t-PA antigen) have a significant association with 
hyperinsulinemia state.3
Almost all studies have demonstrated 
consistent evidence on the presence of 
coagulation disorder and fibrinolysis defect 
in DM population; while similar studies on 
prediabetic population have inconsistent results. 
Many studies which are conducted in Indonesia 
have demonstrated the role of inflammatory 
factors on cardiovascular events. However, 
studies on the role of hemostatic factors, 
particularly the fibrinolysis defect are still 
limited. The aim of our study was to identify the 
role of fibrinolysis defect on various prediabetes 
status by assessing the levels of t-PA antigen and 
PAI-1 activity on various status of prediabetes 
status.
METHODS
Our study was an observational study with 
cross-sectional approach. The population of 
study was 72 subjects who were obtained by 
consecutive sampling when the patients visited 
in prediabetic subjects than those with NGT; and there was a significant association between glycemic status in 
prediabetic subjects and PAI-1 activity.
Keywords: prediabetic, fibrinolytic defect, plasminogen activator inhibitor-1 (PAI-1), tissue-type plasminogen 
activator (t-PA) antigen.
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the outpatient clinic at Department of Internal 
Medicine in Wahidin Sudirohusudo Hospital, 
Labuang Baji Hospital and Prodia Laboratory 
in Makassar. Subjects participated in the study 
were the study population who had met the 
inclusion criteria, i.e. male or female subjects 
aged between 30 and 50 years who were 
willing to participate in the study and signed the 
informed consent form. The exclusion criteria 
were history of diabetes mellitus, coronary heart 
disease, stroke, hypertension, history of taking 
anti-hypertensive agents, anti-thrombotic and 
lipid modifying agent. The study was conducted 
with the approval by the Ethical Committee 
on Biomedical Research in Human, Faculty of 
Medicine, University of Hassanudin with the 
number of approval of 0047/H04.8.4.5.31/PP36-
KOMETIK/2008.
The diagnosis of DM is established based 
on the American Diabetes Association (ADA) 
criteria, i.e. those with classical symptoms of 
diabetes (polyuria, polyphagia and unexplainable 
weight loss) as well as random blood glucose 
levels (RBG) of >200 mg/dL; or fasting blood 
glucose levels (FBG) of >126 mg/dL or 2 hours 
post prandial blood glucose levels (2hPPBG) of 
>200 mg/dL after the loading.13 Normal glucose 
tolerance (NGT) was defined when the fasting 
blood glucose levels was <100 mg/dL and after 
2 hours, the post oral glucose tolerance test levels 
was <140 mg/dL.13 Prediabetics are patients with 
IFBG (Impaired Fasting Blood Glucose) and/or 
Impaired Glucose Tolerance (IGT) as defined by 
the modified ADA criteria (2004). The subjects 
were considered as those with IFBG when the 
fasting blood glucose levels range was 100-125 
mg/dl and 2hPPBG after loading was <140 mg/dl. 
They were considered as subjects with IGT when 
their 2hPPBG levels after glucose loading ranged 
between 140 and 199 mg/dl and their FBG <100 
mg/dl.14 PAI-1 activity was defined as the levels 
of active free PAI-1. The reference value was 1-7 
IU/ml; while the levels of t-PA antigen was t-PA 
antigen calculated quantitatively in the plasma 
with a reference value of 1-20 ng/ml.15
Anthropometric evaluation, blood pressure 
examination, ECG, evaluation on lipid fraction, 
fasting blood glucose levels and 2-hour post 
prandial blood glucose levels using hexokinase 
method of Roche were carried out after the 
subjects had their fasting (no calorie intake) for 
12 hours and 2 hours after glucose loading. Oral 
glucose tolerance test (OGTT) was performed 
based on WHO criteria (1994).
In the evaluation of PAI-1 activity and plasma 
t-PA antigen, 6 ml of blood was withdrawn after 
the subjects had 8-12 hours of fasting between 
7.00 and 10.30 a.m. and put into a tube containing 
citrate with 9 : 1 ratio to prevent diurnal variation 
of PAI-1 levels. Furthermore, the blood was 
immediately processed within <120 minutes. 
After 15 minutes of centrifugation (3000 rpm) 
at 2-8°C, the plasma and serum layers were 
separated and was subsequently put into a cup 
fisher as much as 0.5 cc each and the sample could 
be preserved at -80°C for 6 months. PAI-1 levels 
was measured quantitatively from citrate plasma 
by using the sandwich technique or enzyme-
linked immunosorbent assay (ELISA) utilizing 
the Technozym® PAI-1 kit. The levels of t-PA 
antigen was measured quantitatively from the 
citrate plasma by using Biopool’s TinElize® t-PA, 
an enzyme immunoassay instrument.
The obtained data was analyzed using 
Statistical Package for Social Science (SPSS) 
software program version 17. Afterwards, 
univariate and bivariate analysis were carried 
out. The significance levels of statistic test 
was determined as 5%. Analysis on difference 
between the levels of t-PA antigen and PAI-
1 activity among prediabetic subjects was 
performed using ANOVA (analysis of variance); 
while the association between PAI-1 and 
prediabetic subjects was evaluated using the 
unadjusted Pearson chi square test.
RESULTS
There were 72 subjects who fulfilled the 
inclusion criteria with age range of 30-50 years 
and there were female subjects as many as 
52%. Subject characteristics were categorized 
based on FBG levels, 2hPPBG, lipid profile, 
PAI-1 activity, t-PA antigen levels and waist 
circumference as has been presented in Table 1. 
In our study, we found 18 subjects (25%) 
with NGT and 54 subjects (75%) who were 
prediabetics. An analysis on t-PA antigen levels 
on each glycemic status found that there was 
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a higher t-PA antigen levels in prediabetic 
subjects than subjects with NGT; however, 
the difference of t-PA antigen levels was not 
significant (p=0.253). When the prediabetic 
subjects were categorized separately as the 
subjects with IGT, IFBG and IGT + IFBG and 
then they were compared with the subjects with 
NGT, we subsequently found that the mean 
t-PA antigen levels in prediabetic subjects was 
significantly higher than subjects with NGT 
(p=0.047) (Table 2).
Analysis of PAI-1 activity for each glycemic 
status found that there was a higher level of 
PAI-1 activity in prediabetic subjects than those 
with NGT; however, the difference of PAI-1 
activity was not significant (p=0.094). When the 
prediabetic subjects were categorized separately 
as the subjects with IGT, IFBG and IGT + IFBG 
and compared with the subjects with NGT, we 
found that the mean levels of PAI-1 activity in 
prediabetic subjects was significantly higher than 
subjects with NGT (p=0.024) (Table 3).
By using the Pearson chi square test, we 
found supporting result in line with the findings, 
which was a significant association between 
glycemic status of prediabetic subjects and PAI-1 
activity (p=0.044). The risk of having increased 
PAI-1 activity of more than 7 IU/ml in subjects 
with IGT+IFBG was 4.32 folds than subjects 
with NGT; while in subjects with only IFBG, 
the risk was 2.02 folds compared to the NGT 
subjects (Table 4).
Table 2. The mean level of t-PA antigen in the group of 
subjects with NGT, IGT, IFBG and IGT + IFBG
Subject group Mean (SD) p value
IGT+IFBG (n=15) 11.56 (4.34)
0.047
IFBG (n=16) 9.60 (5.50)
IGT (n=23) 7.83 (2.89)
NGT (n=18) 8.01 (4.06)
Table 3. The mean level of PAI-1 activity in the group of 
subjects with NGT, IGT, IFBG and IGT + IFBG
Subject group Mean (SD) p value
IGT+IFBG (n=15) 11.96 (7.94)
0.024
IFBG (n=16) 8.86 (5.88)
IGT (n=23) 6.40 (6.57)
NGT (n=18) 5.67 (3.92)
Table 4. The correlation between PAI-1 activity and 




n (%) OR (95% CI)
>7 <7
IGT+IFBG 11 (32.35) 4 (10.53) 4.32 (1.88-17.56)
IFBG 9 (23.53) 7 (21.05) 2.02 (1.45-7.20)
NGT 9 (23.53) 14 (39.47) 1.91 (1.25-3.25)
NGT 7 (20.59) 11 (28.95) 1
* p value = 0.044 (Pearson correlation)
DISCUSSION
In our study, we found higher t-PA antigen 
levels in prediabetic subjects than NGT subjects 
although the difference was not significant 
(p=0.253). Nevertheless, when the prediabetic 
subjects were categorized as the subjects with 
IGT + IFBG, IFBG and IGT, we found high 
mean value of t-PA antigen levels, which was 
11.56 (4.34), 9.60 (5.50), and 7.83 (2.89), 
respectively; while the difference of t-PA antigen 
levels was statistically significant (p=0.047).
There are limited studies investigating 
the consistent association between increased 
t-PA antigen levels and the course of illness 
of diabetes mellitus. It may be caused by the 
difficulty in interpreting the standard reference 
value and the measurement may be affected by 
the levels of PAI-1, which is bound in complex 
form with t-PA.16 Lowe et al.17 stated that in type 
Table 1. Data on subject characteristics (n=72)
Variables Mean (SD)
Age (years) 42.23 (5.52)
FBG (mg/dl) 95.91 (14.34)
2hPPBG (mg/dl) 137.65 (33.58)
Total cholesterol (mg/dl) 216.67 (47.23)
LDL cholesterol(mg/dl) 129.51 (33.04)
 HDL cholesterol (mg/dl) 48.39 (15.66)
Triglycerides (mg/dl) 143.43 (35.49)
Waist circumference (cm) 84.52 (10.03)
PAI-1 activity (IU/ml) 7.87 (6.48)
The level of t-PA antigen (ng/ml) 9.02 (4.32)
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2 DM patients, increased t-PA antigen levels is 
only one of markers for cardiovascular events, 
which is different from PAI-1 that have been 
demonstrated and proven by various large-scale 
studies as one of independent risk factors for 
cardiovascular events and type 2 DM.4,5,18,19
Eliasson et al.2 in The Northern Sweden 
MONICA Study have performed a follow-up 
study for 9 years in normal subjects and they 
found that there was a significant increase of t-PA 
antigen levels (p<0.001), which was correlated 
with DM incidence. It has shown that increased 
t-PA antigen has an independent predictive 
value on DM incidence in the future. The 
study also demonstrated that fibrinolysis defect 
characterized by increased t-PA antigen and 
PAI-1 activity and reduced t-PA activity has been 
occurred in prediabetic population before there 
is a further increase in blood glucose levels.2
In our study, we found higher PAI-1 activity 
in prediabetic subjects than subjects with NGT; 
however, the difference was not significant 
(p=0.094). When the prediabetic subjects were 
categorized as the subjects with IGT + IFBG, 
IFBG and IGT, they found high mean value of 
PAI-1, which was 11.96 (7.94), 8.86 (5.88) and 
6.40 (6.57), respectively in which the difference 
of PAI-1 activity was significant statistically 
(p=0.024). 
Pearson chi square test also demonstrated 
that there was a significant association (p=0.044) 
between PAI-1 activity, which had been 
categorized based on the limit value of PAI-1 
activity and the prediabetic glycemic status. 
The results of our study showed that the PAI-1 
activity was >7 IU/ml in subjects with IGT + 
IFBG, which was four times higher than subjects 
with NGT; while in subjects with IFBG, it was 
twice higher than subjects with NGT and subjects 
with IFBG had higher PAI-1 activity of  >7 IU/ml 
than subjects with NGT. In the literature, it has 
been explained that the prediabetic population 
has higher risk on the development of DM and 
the future thromboembolic phenomenon.20,21
Our study is consistent with the results of 
other studies. Meigs et al.3 in The Framingham 
Offspring Study showed a higher PAI-1 levels in 
prediabetic group compared to the NGT group 
and the difference was statistically significant. 
Leurs et al.22 also demonstrate a significantly 
higher PAI-1 levels in subjects with IGT and 
DM compared to subjects with NGT. The 
mechanism of how hyperglycemia can induce 
PAI-1 production has not been fully understood; 
however, in vitro studies have found that 
hyperglycemia state causes stimulation on PAI-
1 gene in the vascular smooth muscle cells.19,23  
After a more detail categorization on 
prediabetic population, we found that the mean 
PAI-1 activity was higher in subjects with IFBG 
than those with IGT. The condition can be 
explained by the rational that in IFBG subjects, 
there is insulin resistance, which predominantly 
occur in the liver; while the insulin sensitivity 
in the muscle is usually normal; on the contrary, 
in subjects with IGT, the insulin resistance 
occurs mainly in the muscle and there is only 
few of them that experience changes of insulin 
sensitivity in the liver. A combinationof insulin 
resistance in the liver and impaired secretion of 
basal insulin has caused increased production 
of glucose in the liver or it is known as the 
endogenous glucose production (EGP) in 
subjects with IFBG; while the combination of 
the second phase impaired insulin secretion and 
the presence of insulin resistance in the muscle 
will be found in subjects with IGT.24 In fasting 
state, the blood glucose levels is determined by 
the amount of glucose produced by the liver 
(EGP), particularly through gluconeogenesis or 
glycogenolysis and the insulin levels produced 
by the pancreas.25 A study by Wayer et al.26 
also explains that increased EGP is found in 
subjects with IFBG; however, increased EGP 
is not found in subjects with IGT and NGT. In 
the same population, it is also said that there 
is a strong association found between PAI-1 
levels and insulin resistance that occurs in the 
liver compared to insulin resistance that occurs 
in the muscles.27
Gluconeogenesis, which is derived from 
breakdown of lipids will cause release of various 
active substances such as free fatty acids and 
harmful adipokines such as proinflammatory 
cytokines and PAI-1.28 It is consistent with the 
results of The Insulin Resistance Atherosclerosis 
Study, which demonstrates that fasting glucose 
has more role in developing future diabetes and 
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its association with increased PAI-1 levels.4 A 
multicenter epidemiological study, the Insulin 
Resistance Atherosclerosis Study (IRAS) by 
Festa et al.5 investigates the association of 
dynamic change of PAI-1 and fibrinogen on type 
2 DM incidence in healthy non-DM individuals. 
The study concludes that increased PAI-1 that 
occurs continuously in subjects with initially 
high PA-1 levels is correlated with the incidence 
of type 2 DM.
There is a association between increased 
PAI-1 and the incidence of diabetes, which is 
based on various reasons.4,5 First, it is assumed 
that there is an equal genetic background between 
PAI-1 expression and the risk of developing type 
2 DM; Second, PAI-1 is assumed to have a role in 
the pathophysiology of type 2 DM causatively; 
and third, there are various similar and affecting 
factors, either on the PAI-1 expression or on 
the development of type 2 DM such as weight, 
insulin resistance, glucocorticoid, triglycerides 
and free fatty acids. Various in vitro and in vivo 
studies have demonstrated that PAI-1 not only 
has a role in the process of atherothrombosis 
of vascular wall, but also has a role in the 
development of adipose tissues and it can control 
the insulin signaling in the adipocytes.28
CONCLUSION
The levels of t-PA antigen is significantly 
higher in subjects with IGT + IFBG and subjects 
with IFBG than those with NGT; while the 
levels of t-PA antigen in IGT is not significantly 
different than those with NGT. The activity of 
PAI-1 is significantly higher in subjects with 
IGT + IFBG and subjects with IFBG than those 
with NGT; while the activity of PAI-1 in subjects 
with IGT is not significantly different from those 
with NGT.
In prediabetic subjects, treatment that has 
been demonstrated to reduce the levels of t-PA 
antigen and PAI-1 activity should be considered. 
An evaluation on markers of fibrinolysis defect 
(t-PA antigen and/or PAI-1) in prediabetic 
subjects is necessary to identify one of the risk 
factors for cardiovascular events.
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